Merck KGAa Archives - MedCity News

Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals

Frank Vinluan — Thu, 21 Sep 2023 13:48:11 +0000

Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.

Merck KGaA opens Shanghai innovation hub, pumps $14M into China seed fund

Alaric DeArment — Fri, 18 Oct 2019 16:59:45 +0000

Another innovation hub, in the southern city of Guangzhou, is planned for November. To date, six startups in China and other Asian countries have taken part in the German drugmaker’s accelerator program.

Three PD-L1 inhibitors see setbacks in their development

Alaric DeArment — Tue, 20 Nov 2018 19:46:18 +0000

Two drugs – Pfizer and Merck KGaA’s Bavencio and AstraZeneca’s Imfinzi – saw Phase III trials fail, while anticipated negative results prompted Roche to withdraw Tecentriq from regulatory review.

Big data and big pharma giants join forces on cancer research effort

Kevin Truong — Tue, 20 Nov 2018 05:08:18 +0000

Merck and Palantir Technologies are forming a joint research venture called Syntropy as a way to offer data analytics tools to healthcare organizations.

Merck KGaA adopts Medisafe medication adherence tool for patients with chronic conditions

Stephanie Baum — Tue, 27 Mar 2018 16:04:18 +0000

As part of the collaboration. Medisafe’s digital health tool will be used for Merck KGaA’s drugs spanning Type 2 diabetes, thyroid disorders, and cardiovascular diseases.

Morning Read: Merck KGaA’s oncology revolution, a litmus test on biotech IPOs

Chris Seper — Mon, 12 Oct 2015 11:40:57 +0000

Blogging will be light today on MedCity News – most of the staff is off for the Columbus Day holiday.

Facebook’s mea culpa over Merck and the legal issue it created

Stephanie Baum — Mon, 28 Nov 2011 22:40:13 +0000

It’s the sort of thing that was inevitable — two companies of the same name […]